Bartell to open three Seattle-area stores this year
SEATTLE Regional retail pharmacy chain Bartell Drugs plans to open three new stores in the Seattle area.
On July 20, Bartell will open a 16,400 sq.-ft. store in the suburb of Lynnwood, Wash., holding a ribbon-cutting event on July 21.
The chain also plans to open a store near Mill Creek, Wash., next month and another in Issaquah, Wash., in September.
“This new store, and the one we will be opening near Mill Creek, underscores our commitment to serving the needs of the residents of Snohomish County,” chairman and CEO George Bartell said in a statement.
The Lynnwood store replaces a 17-year-old store in the nearby suburb of Mukilteo, Wash., and all pharmacy and photo records will be transferred there. The store will include a drive-through pharmacy and Bartell’s PixPlus digital-print photo kiosks and employ 25 workers.
Caraco to acquire rights to several drugs from Forest Labs
NEW YORK Generic drug maker Caraco Pharmaceutical Labs will acquire rights to several drugs from Forest Labs under an asset purchase agreement between the two companies.
Caraco announced the agreement Friday as part of a settlement that it and parent company Sun Pharmaceutical Industries had entered with Forest Labs and Danish drug maker H. Lundbeck concerning Caraco’s regulatory approval application for the anxiety and depression drug Lexapro (escitalopram oxalate). Lundbeck had licensed Lexapro to Forest on an exclusive basis in the United States.
Under the agreement, Caraco will take over commercialization and sale of several products from Forest’s Inwood business, paying Forest an advance against royalties. Meanwhile, Forest will reimburse Caraco for a portion of its legal fees and provide licenses to Caraco for certain Lexapro patents as soon as a third-party generic version with Food and Drug Administration approval hits the market.
Watson Pharmaceuticals gets the OK from FDA for new nicotine polacriliex gum
MORRISTOWN, N.J. Watson Pharmaceuticals, a leader in generic and specialty branded pharmaceuticals, announced its subsidiary, Watson Labs, has been granted approval from the Food and Drug Administration to market its nicotine polacrilex gum.
Nicotine polacrilex gum is the generic equivalent of GlaxoSmithKline Consumer Healthcare’s Nicorette Fruit Chill and Cinnamon Surge Coated gums, all of which are available over-the-counter and used to help people stop smoking.
Watson’s nicotine gum will be available as soon as possible in coated fruit and cinnamon flavors.